Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  New England Journal of Medicine

• Publication date

  1986-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM198604173141601PMID 3515182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum amyloid A protein in familial Mediterranean fever.

  1985cited by this paper
• Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups.

  1982cited by this paper
• Familial Mediterranean fever: report of a large family, review of the literature, and discussion of the frequency of amyloidosis.

  1980cited by this paper
• Prolonged colchicine treatment in four patients with amyloidosis.

  1977cited by this paper
• Letter: Colchicine in familial Mediterranean fever.

  1976cited by this paper
• Mouse amyloid protein AA: Homology with nonimmunoglobulin protein of human and monkey amyloid substance.

  1976cited by this paper
• A controlled trial of colchicine in preventing attacks of familial mediterranean fever.

  1974cited by this paper
• BLOCKAGE OF AMYLOID INDUCTION BY COLCHICINE IN AN ANIMAL MODEL

  1974cited by this paper
• FAMILIAL MEDITERRANEAN FEVER IN ARMENIANS. ANALYSIS OF 100 CASES

  1974cited by this paper
• Colchicine inhibition of casein-induced amyloidosis in mice.

  1974cited by this paper
• Colchicine therapy for familial mediterranean fever. A double-blind trial.

  1974cited by this paper
• Colchicine for familial Mediterranean fever.

  1972cited by this paper
• The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils.

  1972cited by this paper
• The role of amyloidosis in familial mediterranean fever. A population study.

  1968cited by this paper
• Familial Mediterranean fever. A survey of 470 cases and review of the literature.

  1967cited by this paper
• FAMILIAL PAROXYSMAL POLYSEROSITIS. ANALYSIS OF FIFTY CASES.

  1964cited by this paper
• Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF). Further evidence of its genetic nature.

  1962cited by this paper
• Amyloidosis in familial Mediterranean fever. An independent genetically determined character.

  1961cited by this paper
• Familial Mediterranean fever.

  1958cited by this paper

• Colchicine discontinuation in familial Mediterranean fever: short-term outcomes by pre-discontinuation attack frequency

  2026cites this paper
• Familial Mediterranean Fever and Long-Term Cardiovascular Disease Burden.

  2026cites this paper
• Efficacy and Safety of Anakinra in Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Single-Center Real-Life Experience

  2025cites this paper
• Multifaceted pulmonary manifestations of amyloidosis: state-of-the-art update

  2025cites this paper
• Maternal and fetal risks in familial mediterranean fever: focus on adverse pregnancy outcomes

  2025cites this paper
• Exploring and Expanding Secondary Findings Through Exome Sequencing in the Turkish Population

  2025cites this paper
• The needed daily dose of colchicine in patients with Familial Mediterranean Fever may be higher in women: a study on behalf of the JIR cohort

  2025cites this paper
• Renal outcomes and survival in amyloidosis associated with familial Mediterranean fever: A longitudinal study.

  2025cites this paper
• The decline of AA amyloidosis in familial Mediterranean fever is significant, but the story is not over.

  2025cites this paper
• Amyloidosis in Human Inborn Errors of Immunity Predicts Poor Prognosis

  2025cites this paper
• Neuroprotective role of Hippo signaling by microtubule stability control in Caenorhabditis elegans

  2025cites this paper
• Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry.

  2025cites this paper
• The Mediterranean spring-the second revolution (and the first) in the management of familial Mediterranean fever.

  2025cites this paper
• The Evolving Landscape of Amyloid Research

  2025cites this paper
• Inflammatory turmoil within: an exploration of autoinflammatory disease genetic underpinnings, clinical presentations, and therapeutic approaches

  2024cites this paper
• AA Amyloidosis: A Contemporary View

  2024influential citation
• Secondary Prevention of Coronary Heart Disease Based on Residual Inflammatory Risk Assessment

  2024cites this paper
• An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.

  2024cites this paper
• Familial Mediterranean Fever in Childhood

  2024cites this paper
• Amylose AA

  2024cites this paper
• Die häufigsten Fiebersyndrome und autoinflammatorischen Erkrankungen im Erwachsenenalter

  2024cites this paper
• Anakinra-Dependent Recurrent Pericarditis: The Role of the R202Q Variant of the MEFV Gene

  2024cites this paper
• Kidney Disease in Systemic Amyloidosis

  2024cites this paper
• Kidney Transplantation in Patients With AA Amyloidosis: Outcomes in a French Multicenter Cohort.

  2023cites this paper
• Lipids in inflammasome activation and autoinflammatory disorders.

  2023cites this paper
• Seeing Colchicine in a New Light: Repurposing Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease.

  2023cites this paper
• PREDICT-crFMF score: a novel model for predicting colchicine resistance in children with familial Mediterranean fever.

  2023cites this paper
• Gut microbiota alterations are associated with phenotype and genotype in familial Mediterranean fever.

  2023cites this paper
• Therapeutic effects of biological treatments on AA amyloidosis associated with inflammatory bowel disease: a case report and literature review.

  2023cites this paper
• Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

  2023cites this paper
• Colchicine treatment can be discontinued in a selected group of pediatric FMF patients

  2023cites this paper
• Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors.

  2023cites this paper
• First and Second-Trimester Biochemical Serum Markers in Maternal Familial Mediterranean Fever: The Impact of Colchicine Use.

  2023cites this paper
• Old paradigms and new concepts in familial Mediterranean fever (FMF) - an update 2023.

  2023cites this paper
• French protocol for the diagnosis and management of familial Mediterranean fever.

  2023cites this paper
• Pan-immune-inflammation value in FMF patients

  2023cites this paper
• Acute Colchicine Poisoning Resulting in Cardiac Arrest and Death: A Case Report and Literature Review

  2023cites this paper
• Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever

  2022cites this paper
• Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review.

  2022cites this paper
• Mutational Analysis of the MEFV Gene in Egyptian Patients with Familial Mediterranean Fever

  2022cites this paper
• Factors affecting patient-acceptable symptom states and Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever treatment decision in familial Mediterranean fever

  2022cites this paper
• Hereditary Systemic Autoinflammatory Diseases: Therapeutic Stratification

  2022cites this paper
• Interventions for reducing inflammation in familial Mediterranean fever.

  2022cites this paper
• Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review.

  2022cites this paper
• Cognitive Status is Better in Older Adults under Colchicine Treatment: A Case-Control Study

  2022cites this paper
• Mapping of global research on familial Mediterranean fever: a SCI-Expanded-based bibliometric analysis

  2022cites this paper
• The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease

  2022cites this paper
• Evaluation of the controlling nutritional status score and prognostic nutritional index in patients with familial Mediterranean fever

  2022cites this paper
• Colchizin in der pädiatrischen Rheumatologie

  2021cites this paper
• Systemic Disease and the Skin

  2021cites this paper
• Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.

  2021cites this paper
• Immune Dysfunction and Drug Targets in Autoinflammatory Syndromes

  2021cites this paper
• A review on liquid chromatographic analysis of colchicine in the forensic and medical perspective

  2021cites this paper
• The risk of depression and anxiety in patients with familial mediterranean fever - a cross-sectional study.

  2021cites this paper
• Renale Amyloidosen

  2021cites this paper
• [Familial Mediterranean fever in 2020].

  2021cites this paper
• FMF bei Kindern und Jugendlichen

  2021cites this paper
• Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options

  2021cites this paper
• Secondary Amyloidosis Presenting as Ischemic Proctitis

  2021cites this paper
• Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.

  2021cites this paper
• Low‐dose colchicine in type 2 diabetes with microalbuminuria: A double‐blind randomized clinical trial

  2021cites this paper
• Discontinuation of Colchicine Therapy in Children With Familial Mediterranean Fever

  2021cites this paper
• Colchicine efficacy and safety for the treatment of cardiovascular diseases

  2021cites this paper
• Colchicine-new horizons for an ancient drug.

  2021cites this paper
• Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials

  2021cites this paper
• Familial Mediterranean Fever and Asthma.

  2021cites this paper
• Was ist gesichert in der Therapie von autoinflammatorischen Fiebererkrankungen?

  2021cites this paper
• Systemic autoinflammatory disease in adults.

  2021cites this paper
• Colchicin: altes Medikament mit neuem Nutzen

  2021cites this paper
• Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever

  2020cites this paper
• FAMILIAL MEDITERRANEAN FEVER: A GENERAL REVIEW

  2020cites this paper
• The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients

  2020cites this paper
• Prescription of interleukin-1 inhibitors in a French adult cohort of familial Mediterranean fever.

  2020cites this paper
• Ergebnisse der systematischen Literatursuche als Grundlage für die „evidenzbasierten Therapieempfehlungen für FMF-Patienten mit unzureichendem Ansprechen bzw. Unverträglichkeit auf Kolchizin“ der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Rheumatologie

  2020cites this paper
• [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatolo

  2020cites this paper
• Familial Mediterranean Fever without Fever

  2020cites this paper
• Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor

  2020cites this paper
• Colchicine for the treatment of cardiovascular diseases: old drug, new targets.

  2020cites this paper
• Systemic amyloidosis from A (AA) to T (ATTR): a review

  2020cites this paper
• Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review

  2020cites this paper
• How to handle the main drugs to treat autoinflammatory disorders and how we treat common autoinflammatory diseases.

  2020cites this paper
• Colchicine intolerance in FMF patients and primary obstacles for optimal dosing

  2020cites this paper
• A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.

  2020cites this paper
• AA amyloidosis secondary to adult onset Still's disease: About 19 cases.

  2020cites this paper
• Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

  2020cites this paper
• The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review

  2020cites this paper
• Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide

  2020cites this paper
• Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever.

  2020cites this paper
• Familial Mediterranean Fever Complicated by a Triad of Adrenal Crisis: Amyloid Goiter and Cardiac Amyloidosis

  2020cites this paper
• Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients.

  2020cites this paper
• Autoinflammatory Diseases: From Genes To Bedside

  2020cites this paper
• Compliance of Familial Mediterranean Fever Patients With Regular Follow-up Visits and Associated Factors

  2020cites this paper
• Colchicine in Dermatology: Rediscovering an Old Drug with Novel Uses

  2020cites this paper
• Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?

  2020cites this paper
• Reshaping cytoskeleton: different acts of modulatory compounds

  2020cites this paper
• Textbook of Autoinflammation

  2019cites this paper
• Autoinflammatory diseases: State of the art.

  2019cites this paper
• Autoinflammatory Diseases and Amyloidosis

  2019cites this paper
• Evidenzbasierte Therapieempfehlungen für das familiäre Mittelmeerfieber

  2019cites this paper
• British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature.

  2019cites this paper